Considerations when choosing oral chemotherapy: identifying and responding to patient need
S. IRSHAD
mrcp, bsc, mbbs, specialist registrar in medical oncology,
N. MAISEY
md, mbbs, mrcp, consultant medical oncologist,
Corresponding Author
S. IRSHAD mrcp, bsc, mbbs, specialist registrar in medical oncology
Guy's & St Thomas' NHS Foundation Trust, London, UK
Sheeba Irshad, Specialist Registrar Medical Oncology, 4th Floor Management Offices, Bermondsey Wing, Guy's Hospital, St Thomas Street, London SE1 9RT, UK (e-mail: [email protected]). Search for more papers by this authorN. MAISEY md, mbbs, mrcp, consultant medical oncologist
Guy's & St Thomas' NHS Foundation Trust, London, UK
Search for more papers by this authorS. IRSHAD
mrcp, bsc, mbbs, specialist registrar in medical oncology,
N. MAISEY
md, mbbs, mrcp, consultant medical oncologist,
Corresponding Author
S. IRSHAD mrcp, bsc, mbbs, specialist registrar in medical oncology
Guy's & St Thomas' NHS Foundation Trust, London, UK
Sheeba Irshad, Specialist Registrar Medical Oncology, 4th Floor Management Offices, Bermondsey Wing, Guy's Hospital, St Thomas Street, London SE1 9RT, UK (e-mail: [email protected]). Search for more papers by this authorN. MAISEY md, mbbs, mrcp, consultant medical oncologist
Guy's & St Thomas' NHS Foundation Trust, London, UK
Search for more papers by this authorConflict of interest statement: Nil.
Abstract
IRSHAD S. & MAISEY N. (2010) European Journal of Cancer Care19, 5–11Considerations when choosing oral chemotherapy: identifying and responding to patient need
Oral chemotherapeutics are becoming increasingly accepted for the treatment of cancers and their future has never been brighter. They offer a more convenient and less invasive therapeutic option, moving cancer treatment from a predominantly hospital-based day unit into the ambulatory setting. Oral chemotherapy has the potential to maintain patient's quality of life and avoid the complications and costs of intravenous chemotherapy. It offers sustained drug exposure by providing prolonged therapy compared with intermittent IV exposure and lends itself more easily to the delivery of combination therapy. In this article we highlight the expansion of oral chemotherapeutic drug development in cancer treatment and the challenges posed by this change in treatment delivery.
REFERENCES
- Bajetta E., Di bartolomeo M., Mariani L., Cassata A., Artale S., Frustaci S., Pinotti G., Bonetti A., Carreca I., Biasco G., Bonaglia L., Marini G., Iannelli A., Cortinovis D., Ferrario E., Beretta E., Lambiase A. & Buzzoni R. (2004) Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 100, 279–287.
-
Borner M.M.,
Schoffski P.,
De Wit R.,
Caponigro F.,
Comella G.,
Sulkes A.,
Greim G.,
Peters G.J.,
Van Der Born K.,
Wanders J.,
De Boer R.F.,
Martin C. &
Fumoleau P. (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
European Journal of Cancer
38, 349–358.
10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A Google Scholar
- Borner M.M., Bernhard J., Dietrich D., Popescu R., Wernli M., SalettI P., Rauch D., Herrmann R., Koeberle D., Honegger H., Brauchli P., Lanz D. & Roth A.D. (2005) A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Annals of Oncology 16, 282–288.
- Cassidy J., Twelves C., Van Cutsem E., Hoff P., Bajetta E., Boyer M., Bugat R., Burger U., Garin A., Graeven U., Mckendric J., Maroun J., Marshall J., Osterwalder B., Perez-Manga G., Rosso R., Rougier P. & Schilsky R.L. (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Annals of Oncology 13, 566–575.
- Cassidy J., Douillard J.Y., Twelves C., McKendrick J.J., Scheithauer W., Bustovà I., Johnston P.G., Lesniewski-Kmak K., Jelic S., Fountzilas G., Coxon F., Díaz-Rubio E., Maughan T.S., Malzyner A., Bertetto O., Beham A., Figer A.. Dufour P., Patel K.K., Cowell W. & Garrison L.P. (2006) Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. British Journal of Cancer 94, 1122–1129.
- Cassidy J., Clarke S., Diaz-Rubio E., Scheithauer W., Figer A., Wong R., Koski S., Lichinitser M., Yang T.S., Rivera F., Couture F., Sirzen F. & Saltz L. (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Journal of Clinical Oncology 26, 2006–2012.
- Cassidy J., Bridgewater J., Maisey N. & Raouf S. (2009) Oral Chemotherapy Practical Guidance 2009. Roche Ltd, London, England, UK.
- Darba J., Restovic G. & Ramirez De Arellano A. (2008) Economic assessment of capecitabine/cisplatin versus 5-FU/cisplatin regimens in treatment of advanced gastric cancer in Spain. Presented at the 33rd congress of the European Society for Medical Oncology, Stockholm, Sweden, September 12–16, 2008.
- De Gramont A., Bosset J.F., Milan C., Rougier P., Bouche O., Etienne P.L., Morvan F., Louvet C., Guillot T., Francois E. & Bedenne L. (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. Journal of Clinical Oncology 15, 808–815.
- Decision Resources Inc (2005) Decision Resources Survey. Oral chemotherapeutic agents: key success factors and reimbursement issues. A survey of US Oncologists and HMO pharmacy directors.
- Demario M.D. & Ratain M.J. (1998) Oral chemotherapy: rationale and future directions. Journal of Clinical Oncology 16, 2557–2567.
- Di Costanzo F., Sobrero A., Twelves C., Douillard J., Giuliani G., Patel K., Garrison L. & Cassidy J. (2006) Italian economic evaluation of capecitabine vs. bolus 5-FU/LV as adjuvant chemotherapy for patients with Dukes' C colon cancer. Annals of Oncology 17 (suppl 6), 63 (Abstr 130).
- Floren L.C., Bekersky I., Benet L.Z., Mekki Q., Dressler D., Lee J.W., Roberts J.P. & Hebert M.F. (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clinical Pharmacology and Therapeutics 62, 41–49.
- Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., Findlay B.P., Pitot H.C. & Alberts S.R. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. Journal of Clinical Oncology 22, 23–30.
- Harrold K. (2010) Effective management of adverse effects while on oral chemotherapy: implications for nursing practice. European Journal of Cancer Care 19(Suppl. 1), 12–20.
- Hoff P.M., Ansari R., Batist G., Cox J., Kocha W., Kuperminc M., Maroun J., Walde D., Weaver C., Harrison E., Burger H.U., Osterwalder B., Wong A.O. & Wong R. (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. Journal of Clinical Oncology 19, 2282–2292.
-
James R.,
Blanco C. &
Farina C. (2003) Savings in staff time as a result of switching from de Gramont to oral capecitabine for patients with advanced colorectal cancer.
European Journal of Cancer
1 (Suppl.
5), S83.
10.1016/S1359-6349(03)90304-1 Google Scholar
- Jansman F.G., Postma M.J., Van Hartskamp D., Willemse P.H. & Brouwers J.R. (2004) Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clinical Therapeutics 26, 579–589.
-
Lebovits A.H.,
Strain J.J.,
Schleifer S.J.,
Tanaka J.S.,
Bhardwaj S. &
Messe M.R. (1990) Patient noncompliance with self-administered chemotherapy.
Cancer
65, 17–22.
10.1002/1097-0142(19900101)65:1<17::AID-CNCR2820650106>3.0.CO;2-I CAS PubMed Web of Science® Google Scholar
- Liu G., Franssen E., Fitch M.I. & Warner E. (1997) Patient preferences for oral versus intravenous palliative chemotherapy. Journal of Clinical Oncology 15, 110–115.
- Lokich J.J., Ahlgren J.D., Gullo J.J., Philips J.A. & Fryer J.G. (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. Journal of Clinical Oncology 7, 425–432.
- Mcleod H.L. & Evans W.E. (1999) Oral cancer chemotherapy: the promise and the pitfalls. Clinical Cancer Research 5, 2669–2671.
- Maliepaard M., Van Gastelen M.A., Tohgo A., Hausheer F.H., Van Waardenburg R.C., De Jong L.A., Pluim D., Beijnen J.H. & Schellens J.H. (2001) Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clinical Cancer Research 7, 935–941.
- Odani A., Hashimoto Y., Takayanagi K., Otsuki Y., Koue T., Takano M., Yasuhara M., Hattori H., Furusho K. & Inui K. (1996) Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. Biological & Pharmaceutical Bulletin 19, 444–448.
- Partridge A.H., Avorn J., Wang P.S. & Winer E.P. (2002) Adherence to therapy with oral antineoplastic agents. Journal of the National Cancer Institute 94, 652–661.
- Patt Y., Liebmann T., Diamandidis D., Eckhardt G., Javle M., Justice G., Keiser L., Lee F., Miller W. & Lin E. (2004) Final efficacy and safety findings from a phase II trial of capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC). Annals of Oncology 16, 282–288.
- Payne S.A. (1992) A study of quality of life in cancer patients receiving palliative chemotherapy. Social Science & Medicine 35, 1505–1509.
- Piedbois P., Buyse M., Rustum Y., Machover D., Erlichman C. & Carlson R.W. (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. Journal of Clinical Oncology 10, 896–903.
- Poorter R.L., Lauw F.N., Bemelman W.A., Bakker P.J., Taat C.W. & Veenhof C.H. (1996) Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy. European Journal of Cancer 32A, 2262–2266.
- Saltz L.B., Cox J.V., Blanke C., Rosen L.S., Fehrenbacher L., Moore M.J., Maroun J.A., Ackland S.P., Locker P.K., Pirotta N., Elfring G.L. & Miller L.L. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. The New England Journal of Medicine 343, 905–914.
- Scheithauer W., McKendrick J., Begbie S., Borner M., Burns W.I., Burris H.A., Cassidy J., Jodrell D., Koralewski P., Levine E.L., Marschner N., Maroun J., Garcia-Alfonso P., Tujakowski J., Van Hazel G., Wong A., Zaluski J. & Twelves C. (2003) Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Annals of Oncology 14, 1735–1743.
- Sharma S. (2001) Patient selection for oral chemotherapy. Oncology (Williston Park, N.Y.) 15, 33–35.
- Tournigand C., Andre T., Achille E., Lledo G., Flesh M., Mery-Mignard D., Quinaux E., Couteau C., Buyse M., Ganem G., Landi B., Colin P., Louvet C. & De Gramont A. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of Clinical Oncology 22, 229–237.
- Twelves C., Boyer M., Findlay M., Cassidy J., Weitzel C., Barker C., Osterwalder B., Jamieson C. & Hieke K. (2001) Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. European Journal of Cancer 37, 597–604.
- Twelves C., Sheithauer W., McKendrick J., Nowacki M., Seitz J., Van Hazel G., Wong A., Diaz-Rubio E., Gilberg F. & Cassidy J. (2008) Capecitabine versus 5-FU/LV in stage III colon cancer: Updated 5-year efficacy data from X-ACT trial and preliminary analysis of relationship between hand-foot syndrome (HFS) and efficacy. In: American Society of Clinical Oncology, 2008 Gastronintestinal Cancers Symposium, General Poster Session E. (Abstr 274). Orlando, FL, USA.
- Van Cutsem E., Twelves C., Cassidy J., Allman D., Bajetta E., Boyer M., Bugat R., Findlay M., Frings S., Jahn M., Mckendrick J., Osterwalder B., Perez-Manga G., Rosso R., Rougier P., Schmiegel W.H., Seitz J.F., Thompson P., Vieitez J.M., Weitzel C. & Harper P. (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. Journal of Clinical Oncology 19, 4097–4106.
- Van Cutsem E., Hoff P.M., Harper P., Bukowski R.M., Cunningham D., Dufour P., Graeven U., Lokich J., Madajewicz S., Maroun J.A., Marshall J.L., Mitchell E.P., Perez-Manga G., Rougier P., Schmiegel W., Schoelmerich J., Sobrero A. & Schilsky R.L. (2004) Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. British Journal of Cancer 90, 1190–1197.
- Weingart S.N., Flug J., Brouillard D., Morway L., Partridge A., Bartel S., Shulman L.N. & Connor M. (2007) Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ 334, 407.
- Weingart S.N., Brown E., Bach P.B., Eng K., Johnson S.A., Kuzel T.M., Langbaum T.S., Leedy R.D., Muller R.J., Newcomer L.N., O'Brien S., Reinke D., Rubino M., Saltz L. & Walters R.S. (2008) NCCN task force report: oral chemotherapy. Journal of the National Comprehensive Cancer Network: JNCCN 6 (Suppl. 3), S1–S14.
- Yukawa E., Honda T., Ohdo S., Higuchi S. & Aoyama T. (1997) Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update. Journal of Clinical Pharmacology 37, 92–100.
